ClinicalTrials.gg
RecruitingNCT07260032Updated Dec 2, 2025

Determining the Benefits of Exercise on Cardiovascular Risk in PTSD

An interventional study of Exercise in PTSD, Cardiovascular Disease and Cardiovascular Disease Risk Factors, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital — 5 open to participants now, 9 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Massachusetts General Hospital.

Planned enrollment
25th of 27
10 · median 57
Started
2025
with 1 other
No phase
15 of 28
4 open now
Registered
26th of 28
by date

Among the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, this one is the 25th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 15 with no phase, and was the 26th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

5 of the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to use a non-invasive imaging technique called positron emission tomography/magnetic resonance imaging (PET/MRI) to investigate the effects of exercise on brain activity and arterial (blood vessel) inflammation in people with PTSD symptoms and evidence of or elevated risk for artery disease.

03

Conditions studied

  • PTSD
  • Cardiovascular Disease
  • Cardiovascular Disease Risk Factors
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Trauma exposure
  • PTSD symptoms
  • Subclinical atherosclerotic CVD (e.g., coronary, cerebrovascular, or peripheral arterial plaque or calcifications on imaging), clinical atherosclerotic CVD (e.g., myocardial infarction or revascularization), or increased risk for atherosclerotic CVD (i.e., >2 of hypertension, diabetes mellitus, hyperlipidemia, and active smoking)
  • Ability to understand and sign

Exclusion criteria

Exclusion Criteria:

  • History of stroke, brain surgery, or seizure
  • Use of certain CVD medications (e.g., beta-blockers, high-intensity statins [e.g., rosuvastatin 20/40 mg and atorvastatin 40/80 mg], PCSK-9 inhibitors)
  • Psychiatric or cardiovascular medication change within 4 weeks (i.e., stable regimen is allowed)
  • Unstable blood pressure or cardiac arrhythmia
  • Currently in a supervised or graduated exercise program
  • Neurological or systemic inflammatory disease/current systemic anti-inflammatory therapy
  • Moderate/severe alcohol/substance use disorder
  • Current mania/psychosis
  • Weight >300 lbs.
  • Claustrophobia
  • Pregnancy
  • Metal implants
  • Uncontrolled hyperglycemia (HgbA1c>7.5%)
  • Subjects who have had significant radiation exposure as part of research (>2 nuclear tests, computed tomography images, or fluoroscopic procedures) during the preceding 12-months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Exercise

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    The exercise program will consist of specifically designed activities to place a gradually increasing workload on the cardiovascular system.

06

What researchers measure

Primary outcomes

  1. Heart rate

    10-minute resting heart rate will be measured in beats per minute and collected from electrocardiogram (ECG)

    Time frame: Pre-treatment; Post-treatment (12-16 weeks after pre-treatment visit)

  2. Blood pressure

    Systolic and diastolic blood pressure

    Time frame: Pre-treatment; Post-treatment (12-16 weeks after pre-treatment visit)

  3. Heart rate variability

    10-minute resting heart rate variability will be measured using heart rate R-peak interval times collected from electrocardiogram (ECG)

    Time frame: Pre-treatment; Post-treatment (12-16 weeks after pre-treatment visit)

  4. Arterial inflammation

    Aortic and carotid arterial inflammation will be based on uptake of 18F-fluorodeoxyglucose during positron emission tomography in these sites

    Time frame: Pre-treatment; Post-treatment (12-16 weeks after pre-treatment visit)

  5. Bone marrow inflammation

    Bone marrow inflammation will be based on uptake of 18F-fluorodeoxyglucose during positron emission tomography

    Time frame: Pre-treatment; Post-treatment (12-16 weeks after pre-treatment visit)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 2, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07260032
Responsible party
Antonia V. Seligowski, PhD (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Dec 2, 2025
Start date
Feb 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Antonia Seligowski, PhD
Contact
aseligowski@mgh.harvard.edu
617-643-0954

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion